Keyphrases
Vaccine Response
100%
BNT162b2 Vaccine
100%
Omicron Variant
100%
SARS-CoV-2 Omicron
100%
Pfizer-BioNTech BNT162b2
100%
Two-dose
40%
Binding Antibodies
40%
Humoral Immune Response
40%
Variants of Concern
40%
Third Dose
40%
Hospitalization
20%
Neutralizing Antibodies
20%
Vaccination
20%
Antibody Response
20%
Titer
20%
Young children
20%
Immunogenicity
20%
Pediatric Research
20%
Active Research
20%
COVID-19
20%
Beta-gamma
20%
Vulnerable Populations
20%
Vaccine Effectiveness
20%
Plasma Protein Binding
20%
Vaccine-induced Immunity
20%
Vaccination Coverage
20%
Viral Variants
20%
Booster Dose
20%
Virus Spike
20%
Spike Protein
20%
SARS-CoV-2 Virus
20%
Beta Variant
20%
MRNA Vaccine
20%
Emerging Variants
20%
Coronavirus Vaccine
20%
Delta Variant
20%
Gamma Variant
20%
Booster Vaccination
20%
Antibody Durability
20%
Immunology and Microbiology
Antibody Response
100%
Severe Acute Respiratory Syndrome Coronavirus 2
100%
Omicron Coronavirus Variant
100%
Neutralization
50%
Binding Antibody
33%
Humoral Immunity
33%
Booster Dose
33%
Wild Type
16%
Neutralizing Antibody
16%
Blood Plasma
16%
Vaccine Efficacy
16%
Titer
16%
Coronavirinae
16%
Immunogenicity
16%
Virus Spike
16%
Vulnerable Population
16%
Biochemistry, Genetics and Molecular Biology
Antibody Response
100%
SARS Coronavirus
100%
Omicron
100%
Humoral Immunity
33%
Wild Type
16%
Clinical Trial
16%
Neutralizing Antibody
16%
Immunogenicity
16%
Titer
16%
Coronavirinae
16%
Vulnerable Population
16%
Virus Spike
16%
Blood Plasma
16%
mRNA Vaccine
16%